{"document_type": "article", "snippet": "Allegations about Valeant\u2019s practices and its own disclosures while under pressure cause one to wonder.", "type_of_material": "Op-Ed", "web_url": "http://www.nytimes.com/2015/10/27/opinion/is-valeant-pharmaceuticals-the-next-enron.html", "subsection_name": null, "blog": [], "section_name": "Opinion", "source": "The New York Times", "pub_date": "2015-10-27T00:00:00Z", "word_count": "796", "slideshow_credits": null, "news_desk": "OpEd", "byline": {"original": "By JOE NOCERA", "person": [{"role": "reported", "lastname": "NOCERA", "rank": 1, "organization": "", "firstname": "Joe"}]}, "abstract": "Joe Nocera Op-Ed column welcomes investigation into potentially shady relationship between drug giant Valeant Pharmaceuticals and Philidor; details path of Valeant under chief executive J Michael Pearson and questions integrity of its meteoric rise in stock price.", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "name": "organizations", "is_major": "Y"}, {"value": "Philidor Rx Services LLC", "rank": "2", "name": "organizations", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "rank": "3", "name": "subject", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "rank": "4", "name": "persons", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "5", "name": "subject", "is_major": "N"}, {"value": "Biovail Corp", "rank": "6", "name": "organizations", "is_major": "N"}], "print_page": "27", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbWide-v2.png", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbWide-v2.png"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbStandard-v2.png", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbStandard-v2.png"}], "lead_paragraph": "Allegations about Valeant\u2019s practices and its own disclosures while under pressure cause one to wonder.", "headline": {"kicker": "Op-Ed Columnist", "content_kicker": "Op-Ed Columnist", "print_headline": "The Next Enron?", "main": "Is Valeant Pharmaceuticals the Next Enron?"}, "_id": "562f25e438f0d82f94187de3"}